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1. Introduction
The development of radiological imaging techniques for the evaluation of brain tumours has
progressed significantly in recent years. Two modalities that play a crucial role in the evalu‐
ation of brain tumours in preoperative time to detach are computed tomography (CT) and
magnetic resonance imaging (MRI).
Despite the new digital radiological techniques, which are used widely in clinical practice,
imaging methods such as CT and MRI eliminate x-ray from the examination algorithm of
brain tumours. An x-ray of the skull may detect changes that can lead to suspicion of a tu‐
mour in the intracranial space and subsequent examination using CT or MRI.
It is important to distinguish tumoural from non-tumoural lesions, and to determine their
spatial location. New, advanced imaging CT and MRI techniques provide more detailed
characteristics of brain tumours, and thus, more choices of appropriate therapeutic manage‐
ment of the patient. These techniques also play a significant role in monitoring the effect of
the therapy.
Diagnosis of tumours has improved considerably due to the introduction of new imaging
CT and MRI techniques. These techniques, and the contrast medium in particular, provide
anatomical and structural information about brain tumours, and information about the
physiology, metabolism, and haemodynamics of individual tumours. The importance of ra‐
diology imaging techniques, and their role, in the diagnosis of brain tumours are listed in
Tables 1 and 2.
© 2013 Zeleňák et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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MODALITY IMPORTANCE
CT screening method
MRI method of choice
DSA mostly used for determination of blood supply andembolization of hypervascular tumours
US intraoperative navigation
X – ray limited
Conventional invasive X – ray methods obsolete
Table 1. Importance of radiology imaging techniques in the diagnosis of brain tumours.




















monitoring the effect of treatment
exclude recurrence
distinguishing recurrent tumour from radiation necrosis
Table 2. Role of radiology imaging techniques in brain tumours
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2. Conventional imaging methods
For decades, diagnostic imaging dominated conventional non-invasive and invasive meth‐
ods, and later invasive contrast x-ray techniques. During the second half of the twentieth cen‐
tury, a number of different projection x-ray radiographs of the head and their modifications, as
well as complex invasive contrast imaging techniques, such as pneumoencephalography, ven‐
triculography, and myelography, were improved [1]. Another imaging method is ultrasonog‐
raphy, which can be used for neuronavigation during operation of brain tumours.
2.1. Conventional non-invasive X-ray methods
In the past, conventional non-invasive x-ray examination (radiography of the head) was the
basic diagnostic method in neuroradiology. The baseline projections are posteroanterior
(PA) and lateral x-ray projections of the skull. A PA projection is centred by orbitomeatal
lines and provides anatomical information about the skull and frontal structures. A lateral
projection shows the configuration of the skull and the skull base.
Modification of a PA projection by Caldwell with an x-ray beam inclination of 15°–23°, cau‐
dal to the orbitomeatal line, provides a clearer view of the os petrosum. With an x-ray beam
inclination of 37°, caudal to the orbitomeatal line, we obtain a semiaxial Waters projection,
which shows paranasal cavities and structures of the zygomaticomaxillar complex. An x-ray
beam inclination of 30°, caudal to the orbitomeatal line, in the anteroposterior (AP) direction
provides the Towne's projection, which is appropriate for imaging the os spheoidale, foramen
magnum, and pyramids, and their dorsal edges in particular.
Figure 1. Sella turcica (lateral projection): destruction by tumour
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A submentovertical projection is an axial projection of the skull with the x-ray beam passing
approximately perpendicular to the orbitomeatal line, and is suitable for imaging the os sphe‐
noidale and the base middle fossa foramina. The Stenvers projection with a 45° rotation of the
head from the PA line, and with a caudal x-ray beam inclination of 10°–15°, is the most com‐
mon projection for imaging the os petrosum, providing a good display of the tip of the pyra‐
mid, the structures of the inner ear, and the meatus acusticus internus. The Schüller projection
is a lateral projection with a caudal x-ray beam inclination of 30° and is employed for en‐
hanced imaging and evaluation of the processus mastoideus pneumatization. A modification
of these projections is a lateral projection by Runström I, with an x-ray beam inclination of
15° and a projection by Runström II with a caudal x-ray beam inclination of 45° [1]. Other
special projections focus on the sella turcica (Figure 1.), canalis opticus.
2.2. Conventional invasive X-ray methods
Pneumoencephalography is an imaging method in which the lumbar or suboccipital ap‐
proach is used to instill air into the cerebral ventricles and the subarachnoid spaces after re‐
moving approximately 10–30 mL of cerebrospinal fluid [2].
Ventriculography is an imaging method in which, through a trepanation hole, air is intro‐
duced into each lateral brain ventricle after the collection of cerebrospinal fluid [3].
These imaging x-ray methods are currently not used in clinical practice.
Before the era of CT and MRI, panangiography was the essential imaging technique of neu‐
roradiology in the diagnosis of brain tumours. A brain tumour manifests itself in angio‐
graphic images by indirect signs, such as dislocation of intracranial arteries, depending on
tumour size and location; tumoural vessels filling with the contrast medium, tumour vascu‐
larization; or vascular occlusion and stenosis [2].
With the onset of CT and MRI, the position of angiography has gradually changed. Current‐
ly, due to a new generation of digital radiological technology and rapid development of in‐
tracranial catheterization techniques and instrumentation, digital subtraction angiography is
a highly specialized imaging method in interventional radiology, with many therapeutic im‐
plications.
2.3. Ultrasound
Ultrasound is a widely available, non-invasive diagnostic method without negative biologi‐
cal effects. Principally, it is applied, in the primary examination of the brain in prenatal and
postnatal diagnoses, and in the examination of cerebral arteries. Currently, ultrasonography,
used in planning operational strategy and choice of neurosurgery access, has been replaced
by new, and more accurate, neuronavigation systems using MRI data. Ultrasound with a
high-frequency transducer can be used to monitor changes during brain tumour operations
in real time [1] (Figure 2.).
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Figure 2. Intraoperative ultrasound navigation with colour flow mapping, showing peripheral vascularization of a
brain tumour with solid and cystic parts
3. Computed Tomography – CT
From its first test scan on a mouse, in 1967, to current medical practice, the CT scanner has
become a core imaging tool. Initially financed by money from Beatles' record sales, the first
patient scan was performed in 1971. Only 8 years later, a Nobel Prize in Physics and Medi‐
cine was awarded to Gofrey Newbold Hounsfield and Allan McLeod Cormack for their dis‐
covery [4]. The prototype (EMI Ltd.) was installed at Atkinson Morley’s Hospital in South
London where the first patient, a middle aged lady with a suspected frontal lobe tumour,
was scanned on 1st October 1971 [5].
The rapid development of CT scanners, a new generation of CT devices, and advanced post‐
processing technologies in recent years has enabled the creation of progressive, advanced
CT protocols for the diagnosis of individual anatomical regions with respect to the patholog‐
ical processes that can be diagnosed. Technological improvements and new CT applications
in neuroradiology are mainly related to CT angiography and CT perfusion with a dynamic
contrast agent bolus [1].
The basic CT examination of brain tumours involves standard non-contrast enhanced and
contrast enhanced imaging (Figure 3.). Compared to MR, CT is superior in the detection of
calcification and bone abnormalities, and it is also less time consuming.
In CT diagnosis, depending on the type of examination, iodinated contrast agents are ad‐
ministered, in different quantities and by different modes. Iodinated contrast agents are div‐
ided into ionic, high-osmolar contrast agents and non-ionic, low-osmolar or iso-osmolar
contrast agents. Intravenous administration of contrast agents may cause various negative
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allergic reactions, which are divided into early (within 20 min) and late effects. In practice,
non-ionic contrast media are generally preferred as, due to their low osmolarity, they result
in significantly fewer negative effects [6].
Figure 3. Contrast enhanced CT of brain tumour: irregular peripheral enhancement of glioblastoma (the image dis‐
played is of the same patient as displayed in Figure 2)
Examination of blood vessels using CT angiography is a non-invasive imaging method
which is conducted in various ways: imaging individual sections, maximum-intensity pro‐
jection (MIP), shaded surface display (SSD), the volume-rendering technique (VRT), multi-
planar reconstruction (MPR), and virtual angiography. Improvement in the quality of CT
angiography, and the new generation of CT equipment gives rise to the possibility of longer
scans, faster scan times with display of the arterial phase of contrast filling with the lowest
venous infiltration, and better resolution with improved vascular details.
CT perfusion (Figure 4.) in the diagnosis of brain tumours allows assessment of tumours on
the microvascular level through a dynamic scanning sequence during an intravenous bolus
injection of a contrast agent. This is a relatively new technique that is used in neuroimaging
for quantitative and qualitative assessment of cerebral perfusion by the parameters of cere‐
bral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), and time to
peak (TTP). Maps with colour-coded flow rates can be obtained by using postprocessing
software. Due to this technique, it is possible to assess the state of vascularization and hae‐
modynamics of brain tumours and their differentiation [7 - 9].
4. Magnetic resonance imaging – MRI
Historically, many scientists have contributed to the study of NMR (MRI), which led to con‐
struction of reliable MR scanners for clinical practice. Isidor Isaac Rabi in 1930 began by
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studying the magnetic properties of atomic nuclei (Nobel Prize in Physics in 1944) [10]. The
first successful nuclear magnetic resonance experiment with NMR precision measurements
was made independently in 1946 by Felix Bloch and Edward Mills Purcell (they jointly re‐
ceived the Nobel Prize in Physics in 1952). In 1971, Raymond Vahan Damadian, measured
T1 and T2 relaxation times of excised normal and cancerous rat tissue and stated that tu‐
mour tissue had longer relaxation times than normal tissue. He is the inventor of the first
MR Scanning Machine (1977) [11]. In March 1973 Paul C. Lauterbur published the first 2D
NMR images of two 1 mm capillaries filled with water [10] and in 1974 the image of thoracic
cavity of mouse. He called his imaging method zeugmatography. This term was later re‐
placed by NMR imaging [12]. Peter Mansfield with Grannel described the use of magnetic
field gradients to acquire spatial information in NMR. P.C. Lauterbur and Sir Peter Mans‐
field received the Nobel Prize in 1952. The first commercial MR scanner (Picker Ltd.) in Eu‐
rope was installed in 1983 in Manchester Medical School.
Figure 4. CT perfusion of a brain tumour across the solid part of the tumour (the image displayed is of the same pa‐
tient as displayed in Figure 2).
The main advantages of MRI are the possibilities of imaging individual anatomical regions
in vivo with high tissue contrast, imaging in arbitrary planes, non-invasivity, and the ab‐
sence of demonstrable detrimental effects on human health. Qualitative evaluation of tissues
allows for four basic physical attributes: T1 and T2 relaxation, proton density, motion, and
flow.
4.1. Conventional MRI techniques
Conventional MRI techniques provide information about the anatomical conditions of brain
tissue, the tumour itself, and its relationship with its surroundings. In contrast to CT, con‐
ventional MRI techniques are significantly more sensitive, but as they are nonspecific, they
often provide limited information about tumour physiology.
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The conventional MRI protocol in the diagnosis of brain tumours includes standard T1-
weighted imaging (spin echo [SE], turbo spin echo [TSE], gradient echo, three-dimensional
[3D] sequences, and dynamic studies), T2-weighted imaging (SE, fast spin echo [FSE] or
TSE, and 3D sequences), “dark fluid” T2-weighted imaging (proton density [PD] and fluid-
attenuated inversion recovery [FLAIR]), gradient echo (GRE T2, T2 * GRE, and GRE 3D T1),
inversion recovery (IR) (FLAIR, T1 IR, and short-time inversion recovery [STIR]), and fat
suppression (FS) (STIR and T1 FS) [13] (Figure 5.).
Figure 5. Sagittal non-contrast enhanced T1W image: hyperintense signal of pericallosal lipoma.
Brain tumours show variable pathomorphological manifestations in MRI, which depend on
the structure of different types of tumours. They may have a homogeneous or an inhomoge‐
neous structure, and depending on whether they are focal lesions or infiltrative and grow‐
ing, they are sharply contoured or diffuse [14].
In general, brain tumours in T1-weighted imaging are hypo- or isointense and in T2-weighted
imaging are hyper- or isointense. The tumour’s signal is modified by the intralesional propor‐
tion of individual components. Tumours may contain solid, cystic, necrotic, or haemorrhagic
components, fatty tissue, or an increased proportion of protein in intracystic components. Not
all tumours cause oedema of the brain tissue, which may have a different range [13, 15].
In some cases, visualization of brain tumours in non-contrast imaging can be difficult; there‐
fore administration of a paramagnetic contrast agent is necessary. Contrast enhancement of
brain tumours is variable and dependent on tumour neovascularization.
MRI shows intracranial arteries, veins, and venous sinuses at high-quality. Magnetic reso‐
nance angiography (MRA) can be implemented using several techniques: phase-contrast MRA
(PC MRA), time-of-flight MRA (TOF MRA), and contrast-enhanced MRA (CE MRA) [16].
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Tumour angiogenesis can be dynamically monitored in vivo by 3D-CTA and 4D-CE-MRA.
Of the two methods, 3D-CTA has better spatial resolution, but 4D-CE-MRA allows temporal
resolution of tumour angiogenesis [17].
MRA allows detailed evaluation of intracranial vascular structures, not only because of
purely pathological changes of vascular origin, but also in relation to brain tumours.
4.1.1. Contrast agents
In addition to non-contrast enhanced imaging, magnetic resonance examination is realized
with contrast agents, which improves visualization and demarcation of the tumour. Con‐
trast agents used in MRI are paramagnetic substances containing gadolinium chelates; they
cause shortening of the T1 and T2 relaxation times, resulting in a stronger T1 and a lower T2
signal, and they also increase the contrast between two tissues with different quantities of
the contrast agent. Increase of T1 signal is more significant, compared with the degree of
weakness of the T2 signal; therefore T1-weighted sequences are used after contrast adminis‐
tration (Figures 6-8.).
Figure 6. Axial contrast enhanced T1W image: homogeneous enhancement of multiple meningiomas right supraten‐
torial in patient with neurofibromatosis type 2.
Contrast agents for MRI can be divided into several categories: intravenous contrast agents,
which include the majority of non-specific and specific contrast agents; oral contrast agents
for display purposes of the gastrointestinal tract; and interstitial contrast agents. According
to the space distribution of contrast agents, they are classified into extracellular organ-non‐
specific and intracellular organ-specific contrast agents. In the diagnosis of brain tumours
intravenous extracellular organ-non-specific contrast agents are used, which have the ability
to pass through the blood–brain barrier [18].
Different types of contrast enhancement and common types of brain tumour are listed in
Table 3.
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Figure 7. First patient examination. Axial contrast enhanced T1W image displays almost no contrast enhancement in
the right frontal
Figure 8. Second patient examination. Axial contrast enhanced T1W image displays irregular peripheral enhancement
of right frontal tumour (the image displayed is of the same patient as displayed in Figure 7, 3 months later; glioblasto‐
ma was confirmed by histology).
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Different types of contrast enhancement
no enhancement Low grade astrocytoma
diffuse homogeneous Meningioma
diffuse inhomogeneous Pleomorphic xanthoastrocytoma
ring enhancement Metastasis
irregular peripheral enhancement Glioblastoma
mural nodule enhancement Haemangioblastoma
Table 3. Different types of contrast enhancement of brain tumours and common types of brain tumour.
4.2. Advanced MRI techniques
Early and accurate diagnosis is the first precondition of the successful treatment of brain tu‐
mours. The basic method of determining species diagnosis and grading is the histopatholog‐
ical examination. Biopsy is an invasive method with the risk of possible complications. At
the time of the development and practical use of modern, advanced diagnostic techniques,
the role of radiodiagnostic imaging modalities was not limited to the assessment of patho‐
logical-anatomical conditions [9].
Advanced magnetic resonance techniques in neuroradiology evaluate changes at the micro‐
vascular, haemodynamic, and cellular levels of brain tumours, and in addition to structural
changes, evaluate changes at the metabolic and biochemical levels [19].
Incorporation of new diagnostic techniques, such as diffusion-weighted imaging (DWI), dif‐
fusion tensor imaging (DTI), tractography, perfusion-weighted imaging (PWI), magnetic
resonance spectroscopy (MRS), and functional MRI (fMRI), into the diagnostic protocol al‐
lows us to obtain detailed information about tumour lesions. This presents the best possibili‐
ty of accurate grading of brain tumours in the preoperative time, allowing us to select the
most appropriate therapeutic management for the patients [20].
New techniques lead to better quality monitoring of the effects of therapy.
4.2.1. Diffusion-weighted imaging (DWI)
The theory of diffusion is based on constant, disordered, random motion of water molecules
in all directions (Brownian motion). Biological tissues in which diffusion is the same in all
directions is isotropic; if diffusion is restricted in one direction, tissues are anisotropic. The
most common barrier to diffusion is the cell wall. Cerebrospinal fluid is the isotropic field;
diffusion in gray matter in all directions compared to the liquor is limited but also isotropic.
White matter is the anisotropic region because here diffusion progresses with greater inten‐
sity in the direction within axons [21].
DWI is echo-planar imaging that measures the random motion of water molecules (i.e. diffu‐
sion in biological tissue). The diffusion capacity of water protons is tissue-specific and cre‐
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ates a specific contrast on DWI. On diffusion sequences, the motion of water protons in
biological tissue causes changes in the signal. These signal changes are quantified by calcu‐
lating the apparent diffusion coefficient map (ADC) [22] (Figure 9.).
DWI, which is currently a routine part of imaging protocols, plays an important role in the
assessment of the cellularity of biological tissue. In the diagnosis of brain tumours, DWI is
applicable in differential diagnosis of cystic lesions, abscesses, necrosis, and metastases. In
addition, DWI has a fundamental role in the evaluation of the age of brain ischemia, in
imaging of traumatic changes, and in evaluation activities of demyelinating lesions [23].
Possibilities of using the ADC in differential diagnosis of intracranial tumours, and differen‐
tiating peritumoural oedema and infiltration, have been studied since the beginning of the
21st century. Most studies have concluded that the ADC is useful for distinguishing peritu‐
moural infiltration only and cannot provide information on the degree of differentiation of
glial tumours. However, they found that in tumour tissue with high cellularity, ADC values
were reduced compared to tumours with low cellularity; thus the probability of higher
grading is reduced for solid tumours with high values of the ADC. For tumours with a cyst‐
ic component, such as glioblastoma multiforme, the relationship between the ADC and the
grading is below the level of statistical significance [24].
Figure 9. Axial ADC map showing the right frontal hyperintensity of a tumour (the image displayed is of the same
patient as displayed in Figure 7).
4.2.2. Diffusion tensor imaging (DTI)
DTI is an advanced magnetic resonance technique that allows visualization of white matter
tracts, and describes the movement of water molecules by using two parameters, mean dif‐
fusivity (MD) and fractional anisotropy (FA), which represent the directionality of water dif‐
fusion [25].
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The postprocessing of DTI data using software generates maps of FA and ADC using DWI
images. Reduction of FA surrounding white matter of the tumour indicates the suspicion of
peritumoural white matter infiltration by tumoural elements [26]. Using 3D software appli‐
cations, 3D image tracts are created, allowing imaging of the spatial configuration of white
matter structures, such as the corticospinal tract, and configuration of the corpus callosum
[27]. DTI is able to demonstrate structural changes of white matter tracts related to brain tu‐
mours, such as the detection of alterations, integrity, or dislocation of individual tracts (Fig‐
ure 10.).
Thus, DTI provides other important information that can help distinguish infiltrative grow‐
ing tumours from bounded tumours and, together with assessment of the ADC and conven‐
tional MRI with a contrast agent, the grading of tumours can be better specified [28 - 30].
Figure 10. DTI: destruction and deviation of white matter tracts by anaplastic astrocytoma.
4.2.3. Perfusion-weighted imaging (PWI)
The rapid growth of cells is a result of the increased metabolic demands of a tumour. Cellu‐
lar hypoglycaemia and hypoxia result in the production of cytokines of angiogenesis (vaso‐
active endothelial growth factor) followed by tumour neovascularization, which leads to a
higher volume of blood flow through tumour tissue. Tumour neovascularization and hae‐
modynamic changes are the basic principles of perfusion MRI, which evaluate the blood
supply to brain tissue by four parameters: CBV (the quantity of blood in a given volume in
mL/100mg), CBF (the blood flow in brain tissue in mL/100g/min), MTT (the average time for
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arteriovenous passage of blood in a given volume in seconds), and TTP (the average time to
maximum density in the scanning area in seconds) [31, 32].
PWI uses fast, dynamic, epiplanar imaging sequences with a bolus of a paramagnetic con‐
trast agent, 0.2 mmol/kg body weight, at an injection rate of 5 mL/s, approximately 5-10 sec‐
onds after the start of imaging sequences, followed by an injection of 20-30 mL of saline. The
passage of the contrast agent through vascularized parts of the tumour leads to a reduction
in signal intensity. Converting the values of individual parameters by postprocessing to the
colour range creates maps with different blood flows. Regional cerebral, and tumour, vascu‐
larity is correlated with the CBV.
With PWI it is possible to determine tumour grading non-invasively. In general, high-grade
tumours have higher CBV values than low-grade tumours. PWI is also used for localization
of the parts of a tumour with a high degree of vascularity for the purpose of stereotactic bi‐
opsy. PWI helps to define the edge of a tumour, which is important in planning surgical
treatment radiotherapy. PWI is also used to monitor the effect of treatment on patients. In
the field of radiation changes, using conventional magnetic resonance techniques, it is diffi‐
cult to differentiate the eventual recurrence of a tumour. Postirradiation changes have lower
CBV values, and through PWI, it is possible to detect areas with increased perfusion, which
correspond to tumour recurrence. Increasing specificity in these cases allows the combina‐
tion of PWI with MRS [33].
4.2.4. Magnetic resonance spectroscopy (MRS)
Based on recent achievements in the field of MRS, the diagnostic proportion of proton MRS
has significantly increased, in the past decade progressing from basic and clinical research to
routine clinical practice. MRS is a non-invasive method and currently is part of the ad‐
vanced diagnostic protocol in neuroradiology. MRS can determine pathological changes in
brain tissue long before conventional techniques [34].
MRS provides biochemical and metabolic information about brain tumours and their sur‐
rounding tissues. Thus MRS, contributes significantly to the distinguishing of tumour from
non-tumour lesions, the type of diagnosis and tumour grading in preoperative time, oedema
from infiltrative growing tumours, the monitoring of tumour response to treatment and dis‐
tinguishing postirradiation necrosis from tumour recurrence [35].
MRS by non-invasive and non-destructive methods detects, in vivo in brain tissue, diagnos‐
tically important compounds such as those containing choline (Cho – a key marker of cell
membrane stability), creatine (Cr – an indicator of the energy status, often used as a refer‐
ence value), N-acetylaspartate (NAA – the main indicator of the structure and function of
neurons), lactate (Lac – in normal tissue its concentration is on the edge of detectability and
is increased in anaerobic metabolism), and lipids. The magnetic resonance spectrum of hu‐
man brain metabolites is relatively constant [36].
Changes in biochemical processes at the cellular level precede macroscopic changes; there‐
fore, MRS is able to detect the development of pathological processes in brain tissue before
conventional MRI techniques. MRS and MRI use magnetic characteristics of the atomic nu‐
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cleus; in obtaining the signal, they work on the same physical principle, but the data proc‐
essing and interpretation for each are different. MRI provides detailed information about the
pathological-anatomical state of brain tissue [37].
Whereas, MRS detects metabolic signals and results in a spectrum in which the position of
the signal of a specific metabolite is expressed on the horizontal axis in chemical shifts speci‐
fied in parts per million (ppm), and the vertical axis reflects the intensity of the signal. The
chemical shift and shape of the signal is characteristic for each metabolite [38] (Figure 11.).
Figure 11. MRS: a typical sample 1H MR spectrum in the lesion. Cre2, Cho, Cre, NAA, lac (the image displayed is of the
same patient as displayed in Figure 10).
In practice, there are two basic techniques of MRS, single voxel spectroscopy (SVS) and
chemical shift imaging (CSI). The result of SVS is one spectrum, which shows the overall
distribution of individual metabolites in a limited volume of tissue (voxel) in a volume of
2-8 mL. CSI measures the concentration of metabolites in a selected volume of brain tissue
divided into many small voxels. The result is an individual spectrum for each voxel, and the
imaging of the distribution of the concentration of individual metabolites in the examined
area is produced as a spectroscopic map (Figure 12.).
In clinical practice, MRS is realized through the anatomical imaging of brain tissue using
conventional MRI. The spectra are displayed together with conventional MRI images, which
characterize the anatomical location of the measured area selected for spectroscopy [38].
The results of the spectra are evaluated by the relative intensity of the signals and the ratios
of observed metabolites are typically set to creatine or choline (for example, NAA/Cr, NAA/
Cho, or NAA/Cr + Cho). Different types of tumours are manifested by a characteristic spec‐
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troscopic profile. Primary tumours are characterized by reducing the concentrations of NAA
and N-acetylaspartylglutamate, Cr, and creatinephosphate, and increasing the concentra‐
tions of Cho and (in astrocytoma) inositol (Ins). Increased concentrations of Lac and lipids
(Lip) are characteristic of necrosis. Peritumoural oedema is characterized by low concentra‐
tions of all metabolites. The interpretation of results may not be accurate using ratios in the
evaluation of the spectra; therefore, different quantification programs using standard refer‐
ence values are currently being tested and used [35 - 36].
Figure 12. MRS: Coloured metabolic map of the metabolic ratio of total cholines to the signal of the total NAA signal
(not resolved to its components), tCho:tNAA (the imaged displayed is of the same patient as displayed in Figure 10).
4.2.5. Functional magnetic resonance imaging (fMRI)
Functional magnetic resonance imaging (fMRI) is an MRI procedure that indirectly meas‐
ures the brain activity by means of deoxyhaemoglobin concentration or blood perfusion
changes.
The 1st technique, known as BOLD (blood oxygenation level dependent), is the most popu‐
lar and frequently used [39]; a relative decrease in deoxyhaemoglobin concentration in the
active brain tissue, due to an excessive increase of regional blood flow, and corresponding
increase of oxyhaemoglobin. Oxyhaemoglobin is, however, less effectively deoxygenated by
active brain tissue compared to inactive brain tissue in physiological conditions. Relative
changes of diamagnetic oxyhaemoglobin and paramagnetic deoxyhaemoglobin can be easi‐
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ly measured by fast T2-weighted echo-planar (EPI) acquisitions. Their temporal resolution,
approximately 100 ms per image slice, is good enough to compare several brain images in
rest and active (performing sensory, motor or cognitive task) conditions. The statistical maps
that result from this, coregistered with structural MRI (Figure 13.), can provide precise infor‐
mation (in the order of millimetres) about the position and the size of brain regions involved
in the processing of each respective task, and, sometimes the dynamics of such processing.
The 2nd group of techniques can evaluate the changes of blood flow in brain tissue using
special exogenous diffusible tracers like fluorinated halocarbons, deuterated water, 17O -wa‐
ter and 13C-hydrocarbons, or magnetically labelled endogenous blood water (arterial spin la‐
belled perfusion, ASL). The latter technique is non-invasive and very promising for future
clinical applications. It can substitute some nuclear medicine diagnostic methods while pro‐
viding images with better spatial and temporal resolution. Compared to BOLD techniques,
ASL can provide not only relative differential maps, but it also provides quantifiable infor‐
mation about absolute blood flow values (in ml/g/min) in selected brain regions [40]. Thus,
it can show the regions activated by some tasks, and also pathological tissue with increased
or decreased perfusion compared to normal brain tissue [41]. However, the intrinsic signal-
to-noise ratio of ASL is lower compared to BOLD measurements, and currently the majority
of scanners are not equipped with the respective product sequences to perform routine clini‐
cal ASL procedures.
Figure 13. fMRI: activation of motor cortex during physical stimulation.
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Presently, in tumour imaging, fMRI is used predominantly for the preoperative localization
of eloquent cortical regions that may have been displaced, distorted or compressed by the
tumour [42]. FMRI can provide an alternative to invasive mapping techniques (IMTs), with
many benefits, particularly in those patients that are unable to undergo awake craniotomy
or other stereotactic diagnostic procedures. FMRI data can be very helpful in neuronaviga‐
tion, especially if the eloquent region is hidden in the depth of sulci and/or cannot be stimu‐
lated during the surgery [43].
The sensitivity of fMRI recordings can be increased by the use of stronger magnetic fields. A
shorter scanning procedure, higher signal-to-noise-ratio, and increased spatial resolution of
the resultant images favour the usage of 3T and are stronger compared to conventional 1,5T
scanners [44].
However, the limitations of fMRI are not a result of poor engineering or the low power of
the scanners; the main pitfalls are due to complicated functional brain organization and in‐
appropriate diagnostic protocols that ignore this organization [45]. There are always several
brain regions involved in the processing of every sensory/motor/cognitive task. It is upon
the examiner to choose the best one, to adjust the statistical thresholds of the fMRI map
(which determines the number and the size of activated brain regions), and to recognize
which regions are eloquent.
A coregistration of the data provided by several different functional and/or structural MRI
techniques (e.g. BOLD, ASL, diffusion tensor imaging, MR spectroscopy, 23Na-MRI) is suita‐
ble for future improvements of functional MRI diagnostics.
4.2.6. Neuronavigation and intraoperative imaging modalities
Introduction of CT, MRI, and microsurgical operating techniques into clinical practice have
resulted in progress in the neurosurgical therapy of brain tumours. The application of new
MRI techniques and microsurgery allows for the resection of tumours in functionally impor‐
tant brain regions.
Neuronavigation is a common method of preoperative localization of brain tumours. It uses
imaging materials of preoperative MRI examinations, 3D sequences and DTI and fMRI data,
that are transferred to a computer database of a neuronavigation device; which, after data
processing and registering of the patient's head position, allows for planning of an optimal
trajectory for operating on the brain tumour [46].
According to the virtual reality planning, neurosurgeons could obtain more anatomic infor‐
mation and choose the best approach for tumour resection, which would result in a better
prognosis for patients [47].
The disadvantage of current navigation systems is that it is impossible to update data dur‐
ing the neurosurgical procedure. A shift in brain structures and tracts of white matter as a
result of the evacuation of cerebrospinal fluid, tumour resection, or gravity makes naviga‐
tion inaccurate. These disadvantages deal intraoperative using of imaging methods – intrao‐
perative ultrasonography and MRI [48].
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Intraoperative  MRI  displays  actual  dynamic  changes  in  deformable  brain  tissue  during
surgery, and helps in early detection of potential tumour residue. Data transfer from in‐
traoperative  MRI  to  the  neuronavigation  system is  possible,  and  data  for  neuronaviga‐
tion can be updated repeatedly.  For this purpose,  different types of  magnetic  resonance
devices are used. The presence of a magnetic field requires the use of compatible surgi‐
cal instruments.
Intraoperative ultrasonography with new devices and high resolution is a cheaper alterna‐
tive to MRI, with the advantage of imaging in real time; it provides actual images of the tu‐
mour, surrounding structures, and major blood vessels during surgery [1].
5. Digital subtraction angiography - DSA
Digital subtraction angiography (DSA) is a computer-assisted x-ray technique that subtracts
images of bone and soft tissue to permit viewing of the cardiovascular system [49].
At the beginning of the process of subtraction, an image (the mask) is obtained before arrival
of contrast material at the area of interest, and the mask image is placed into one of two digi‐
tal memories. Then, one or more subsequent images are obtained after the arrival of a con‐
trast bolus and placed into a second digital memory. The mask image is digitally subtracted
from the succeeding contrast image, resulting in contrast-filled structures that are rendered
visible free of background detail. Subtraction is performed in real time [50].
Iodine contrast media are used for the visualization of vessels, however cerebral angiogra‐
phy using gadolinium as an alternative contrast medium in a patient with severe allergy to
iodinated contrast medium may be performed [51].
Radiation, today known as X-rays, was discovered by the German physicist Wilhelm Rönt‐
gen (March 27, 1845–February 10, 1923) on November 8, 1895 [52]. Discovery of X-rays is
ranked as one of the best discoveries in medicine. X-rays are electromagnetic waves. The
range of wavelengths corresponding to diagnostic imaging span from about 0.1 nm (at 12.4
keV) to 0.01 nm (at 124 keV) [53]. This type of radiation is ionizing.
In a  vacuum X-ray tube,  the electrons that  make up the beam are emitted by a  heated
cathode filament.  The electrons are then focused and accelerated towards the focal  spot
by a high voltage that is applied between the cathode filament and the anode. A genera‐
tor is used to supply the X-ray tube with a controlled high voltage between the cathode
and anode, and a controlled current to the cathode. The electron beam strikes the rotat‐
ing anode “target” and part  of  its  kinetic  energy (less  than 1%) is  converted into X-ray
photons, while the rest is converted into heat, which heats up the anode. The X-ray beam
leaves  the  tube  through the  tube  window and passes  onto  the  patient.  Some of  the  X-
rays pass through the patient,  while  some are absorbed.  The resulting radiation pattern
is detected by a flat panel digital X-ray detector (FPD).
FPD system is superior to the image intensifier as it  visualizes small intracranial vessels
combined with a significant reduction of radiation dose, and is able to create high-quali‐
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ty 3D DSA images on which high spatial resolution allows precise visualization of small
vessels,  such  as  perforating  vessels  [54].  DSA  images  are  then  displayed  on  the  LCD
monitor  with  high  resolution  and  different  screen  layouts,  which  can  be  connected  to
several image sources.
The first carotid angiography was performed by Portuguese Egas Moniz (1874-1955) in 1927;
he is considered as a pioneer of cerebral angiography. He reported the first case of cerebral
angiography at the Societe de Neurologie in Paris on July 7, 1927 [55]. Surprisingly, most an‐
giograms were performed to visualize the intracranial portion of the carotids in cases of tu‐
mours, to look for abnormal displacement of arterial branches, with little interest in the
vascular disease itself [56].
The technique, how to obtain safe access to blood vessels was published by Sven-Ivar Sel‐
dinger (1921-1998) in 1953 [57]. DSA is an invasive technique, performed using a catheter;
the most commonly used approach is the transfemoral approach. At the end of angiogra‐
phy, the puncture site can be safely closed by a closure device [58].
DSA is used to detect the blood vessels supplying the brain tumours, and also to control the
hypervascular tumour embolization (meningiomas, paragangliomas, haemangiopericyto‐
mas, juvenile nasopharyngeal angiofibromas and intraaxially located tumours: haemangio‐
blastomas (Figure 14.), hypervascularized metastases and ependymomas). Presurgical or
palliative embolization of a tumour can be performed by either an intraarterial catheteriza‐
tion approach or direct puncture of the tumour artery [59].
DSA may also be used for a balloon occlusion test [60]. Although 4D-CE-MRA may be use‐
ful for evaluating tumour stain in hypervascular brain, head and neck tumours, it is not able
to replace DSA in planning interventional procedures [61].
Modern biplane DSA devices are very useful for neurovascular interventions, which also al‐
lows: 2D and 3D navigation for advanced embolization guidance; overlay of a DSA refer‐
ence image over the matching live fluoro for guidance with less contrast media and less
dose; cross-sectional imaging to view anatomical structures of tumours in combination with
the feeding vessels of the tumour; single-colour vascular flow visualization from a 2D DSA
image series to visualize tumour perfusion tumour vascularization, tumour blush and dem‐
onstrate postembolization result; to fuse the dataset with a preprocedural CT, MR or PET
image to show tumour activity; synchronize the 3D image to the gantry position; PACS con‐
nectivity; the reporting of patient exposure following an intervention.
Modern systems update dynamically to movements of the C-arm, table, zoom and source-
to-image distance to facilitate efficient workflow during interventional procedures. By pro‐
viding more effective and faster guidance, this potentially reduces the use of contrast agents
and radiation dose. Pulse frequencies can be adapted to clinical needs according to the
ALARA principle (As Low as Reasonably Achievable).
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Figure 14. DSA (right vertebral angiogram): intra-axial hypervascularized haemangioblastoma supplied mainly by
right anterior inferior cerebellar artery.
6. Conclusion
Radiology has an important role in the diagnosis of brain tumours. A significant factor for
success in the treatment of brain tumours is the determination of the extent of the tumour
and infiltration of important structures using the CT and MRI imaging methods. Currently,
conventional CT protocols, and particularly MRI protocols, have been expanded by sophisti‐
cated new techniques that are used in practice. They have significantly contributed to the
more detailed species diagnosis of tumours, and to a more accurate estimate of their malig‐
nant potential and relationship to the surrounding tissue. With the new techniques, we can
evaluate not only detailed tumour morphology, but also the character of the tumour at the
microvascular, haemodynamic and cellular level, and the metabolic and biochemical level.
With new methods of imaging, exact operational planning approaches on brain tissue can be
achieved. Postoperative monitoring of the effect of therapy is highly refined, with more ac‐
curate detection of tumour recurrence, and differentiation from postoperative and postra‐
diation changes. Some characteristics of selected brain tumours are presented in Tables 4
and 5.
Hybrid systems have presented new possibilities in brain tumour imaging. The hybrid brain
PET/MR allows for molecular, anatomical and functional imaging with uncompromised MR
image quality and a high accordance of PET results between PET/MR and PET/CT [62].
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Characteristics of selected intracranial tumours














Astrocytoma infiltrative / non-infiltrative types
No contrast enhancement in low-
grade astrocytomas







most common (85% of cerebellar
astrocytomas); solid/cystic focal
lesion
well-demarcated cysts with a
contrast enhancing mural nodule
Brainstem
astrocytoma
95% of brainstem neoplasms
variable MR appearance (may be







may be present in up to 80%;
hydrocephalus is often observed
variable contrast enhancement
Ependymoma
arise from the ependyma of the
fourth ventricle
foci of high intensity (necrotic areas
and cysts) and low intensity
(calcifications or haemorrhage) on
T2-WI
Haemangioblastoma
Uncommon except in patients with
von Hippel Lindau disease
small contrast-enhancing nodule
with or without cyst
Teratoma
in infants,
second most commoon type of
germ cell tumours, occurs more
common in males, may contains
calcification, cysts; fatty
components can cause a chemical
meningitis













may contain cysts, lipid
components, and calcification




Table 4. Characteristics of selected intracranial tumours in children
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Characteristics of selected intracranial tumours



























approximately 33% of intracranial
tumours
circumscribed sphenoid peripheral
to nodular enhancing lesion, often
multiple, axonal oedema
Glioblastoma
most common primary CNS tumour,
highly malignant, can cross corpus
callosum
irregularly marginated tumour with
necrosis and peripheral oedema
Astrocytoma infiltrative / non-infiltrative types
No contrast enhancement in low-
grade astrocytomas
Lipoma
benign fatty lesion commonly
affecting corpus callosum
density of fat, high T1-WI signal,
signal suppression on FS (fat
suppression) or STIR method




especially lung and breast cancer, also
melanoma, thyroid malignancies, and
renal cell cancer; can present with
obstructive hydrocephalus
melanoma MTS – high T1-WI signal
Haemangioblastoma
typically multiple in patients with von
Hippel-Lindau disease
small contrast-enhancing nodule
with or without cyst
Lymphoma
primary CNS lymphoma – more
common than secondary (can involve






Choroid plexus papilloma of fourth
ventricle, rare neoplasm, usually
prominent contrast enhancement,
calcifications may be associated,
hydrocephalus
MR features of choroid plexus











most common extraaxial tumour,
usually benign, multiple in
neurofibromatosis type 2
dural-based lesions (the dural tail
sign), prominent enhancement,
calcifications may be associated




less than normal pituitary tissue –




90% of intracranial schwannomas
75% of lesions in the cerebellopontine
angle cisterns
prominent contrast enhancement;
can be heterogeneous in large
lesions
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Characteristics of selected intracranial tumours




















n) multiple seen with neurofibromatosis
type 2
Meningioma
can result in compression of dural








tubular zones of flow voids; often
erosive bone changes
Table 5. Characteristics of selected intracranial tumours in adults
Tables 4 and 5 are modified according to [13 – 14, 63 - 64].
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